Pfizer blazes new research path with university deal; Tougher FDA bars seven researchers from new studies;

> The latest performance-enhancing drug on the field is one that also boosts performance in the bedroom. Pfizer's best-selling ED drug Sildenafil, according to a study in the Journal of Applied Physiology, improved lung function and blood flow to cyclists' muscles at high altitudes. Report

> Taking a page from the biotech playbook, Pfizer has just inked a three-year, $9.5 million research collaboration pact with the University of California, San Francisco. The money will be used to fund early scientific work into new therapies and devices. Pfizer report

> So far this year a more vigilant FDA has barred seven physicians from conducting medical research work. FDA report

> Encysive is now a wholly owned subsidiary of Pfizer via its merger with Pfizer's Explorer Acquisition; Pfizer has now acquired all outstanding shares of the company's common stock for $2.35 per share. Report.

> A Moscow-based market research firm called Pharmexpert revealed that Russian domestic growth is falling behind imports while drug prices continue to increase in the commercial sector.  Report

> Amylin Pharmaceuticals stock is back on the rise after a dip on Monday in the face of a competitor's positive findings in the diabetes space.  Report.  

> Legislation passed recently that will allow pharmacies to share prescription drug information with direct mail companies, raising both privacy and profit concerns.  Report.

> GlaxoSmithKline is cutting 40 percent of its R&D team at some U.S. sites after agreeing to fork up $720 million for Sirtris Pharmaceuticals. Report 

> AstraZeneca says it will appeal to the Alabama Supreme Court if a county circuit judge does not overrule a $215 drug fraud ruling against the company for allegedly charging Medicaid patients too much for prescription drugs. Report

> Sanofi-Aventis said that a trial of Acomplia showed a significant improvement in glucose control in comparison to insulin among patients with type 2 diabetes. Report

> One of Alexza Pharmaceuticals' drug candidates failed a key proof-of-concept trial, sending its stock into a swoon. Report

> BioSante Pharmaceuticals has brought in Deutsche Bank to advise the company on its "strategic alternatives." BioSante report

> Few disease targets are as attractive to drug developers as obesity. And few are as complex. Researchers and drug companies are routinely stumped in trying to develop a pill that can trump the body's 'guerrilla tactics' when it comes to weight loss. Obesity report

> Researchers at the University of Virginia say that an epilepsy drug--topiramate--can reduce alcoholics' craving for a drink as well as promote their overall health. Report

> Taking a page from the biotech playbook, Pfizer has just inked a three-year, $9.5 million research collaboration pact with the University of California, San Francisco. The money will be used to fund early scientific work into new therapies and devices. Pfizer report

And Finally... Perrigo got jiggy with last month's just-under-a-minute video clip aimed at drawing pharma industry talent, which continues to draw a few new viewers.  Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.